McKesson Secures $5B Credit Facility Ahead of Potential M&A Activity
McKesson Corporation (NYSE: MCK) has positioned itself for potential large-scale acquisitions after securing a new $5 billion revolving credit facility, according to an SEC filing dated April 28, 2026. The healthcare distribution giant replaced two existing credit facilities totaling $5 billion with a single, more flexible financing arrangement that runs through April 2031.
The Deal
The new revolving credit facility, arranged with Bank of America as administrative agent, consolidates McKesson's previous financing structures into a unified $5 billion line of credit. This replaces the company's $1 billion 364-day facility that was set to mature in May 2026 and a $4 billion five-year facility scheduled to mature in November 2029.
Key terms of the new facility include a $4.5 billion sublimit for borrowings in Canadian Dollars, British Pound Sterling, and Euros—up from the previous $3.6 billion sublimit. The facility features competitive interest rates based on a ratings-based pricing grid, with SOFR-based loans carrying margins between 0.625% and 1.25%.
Notably, the agreement includes a provision that temporarily relaxes the company's debt covenant from 4.25x to 4.75x total debt to Consolidated EBITDA ratio upon completing an acquisition involving cash consideration of at least $500 million. This strategic flexibility signals McKesson's readiness to pursue significant M&A opportunities.
Strategic Rationale
The timing and structure of this refinancing suggest McKesson is preparing for transformative growth opportunities in the healthcare distribution and services sectors. By consolidating its credit facilities five years before the larger facility's maturation, the company gains several strategic advantages.
First, the extended maturity to 2031 provides long-term financial stability and eliminates near-term refinancing risk. Second, the built-in acquisition toggle for the debt covenant demonstrates management's intention to maintain financial flexibility for opportunistic deals while preserving investment-grade credit metrics.
The exclusion of Medical-Surgical Solutions segment debt from covenant calculations is particularly telling. This carve-out suggests McKesson may be considering strategic moves specific to this division, whether through acquisitions to strengthen its position in medical supplies distribution or potential divestitures to focus on higher-margin pharmaceutical distribution.
The increased international borrowing sublimit from $3.6 billion to $4.5 billion also indicates potential cross-border acquisition activity. With healthcare consolidation accelerating globally, McKesson appears positioned to capitalize on opportunities in Canada, the UK, and European markets where it already maintains operations.
What to Watch
Several factors warrant close monitoring as McKesson deploys this enhanced financial flexibility. The healthcare distribution landscape continues to consolidate, with mounting pressure from both Amazon's healthcare ambitions and traditional competitors seeking scale advantages.
Regulatory considerations will play a crucial role in any major acquisition strategy. The Federal Trade Commission has shown increased scrutiny of healthcare consolidation, particularly vertical integration between distributors, pharmacy benefit managers, and healthcare providers. Any transformative deal exceeding $500 million—the threshold for covenant relaxation—would likely face extensive regulatory review.
The Medical-Surgical Solutions segment bears particular attention given its special treatment in the credit agreement. This division has faced margin pressure from supply chain disruptions and could be a candidate for either strategic acquisitions to achieve scale or divestiture if McKesson chooses to focus exclusively on pharmaceutical distribution.
Investors should also monitor McKesson's leverage trajectory. With no outstanding borrowings on the terminated facilities, the company enters this new arrangement with significant dry powder. The 4.25x leverage covenant provides substantial headroom for debt-financed acquisitions while maintaining investment-grade ratings.
The international borrowing capacity expansion suggests McKesson may pursue opportunities in markets experiencing healthcare infrastructure development or consolidation. European markets, in particular, present acquisition targets as governments seek efficiency in drug distribution amid budget pressures.
This strategic refinancing positions McKesson to act decisively when the right acquisition opportunity emerges, whether in pharmaceutical distribution, specialty pharmacy, healthcare technology, or adjacent services. The company's proactive approach to securing favorable financing terms well ahead of maturity dates demonstrates management's confidence in executing its growth strategy through 2031.